Raab GT, et al. - Researchers analyzed receipt of first-line bevacizumab [used in conjunction with first-line chemotherapy to treat metastatic colon cancer] and predictors of its use among 3785 older patients with stage IV colon cancer. To identify patients with stage IV colon cancer diagnosed from 2005 to 2013 who received FOLFOX (5-fluorouracil/leucovorin/oxaliplatin) or FOLFIRI (5-fluorouracil/leucovorin/irinotecan) as first-line therapy, data from the Surveillance, Epidemiology, and End Results-Medicare dataset were used. As part of their first-line therapy for stage IV colon cancer, more than half of the elderly patients got bevacizumab. Since 2005, bevacizumab use has slowly decreased. Bevacizumab has not been replaced by new anti-epidermal growth factor receptor treatments, as first-line biologic use, in general, has also declined over this time period.